Relationship Between Antithymocyte Globulin Concentrations and Lymphocyte Sub-Populations in Kidney Transplant Patients.
Journal
Clinical pharmacokinetics
ISSN: 1179-1926
Titre abrégé: Clin Pharmacokinet
Pays: Switzerland
ID NLM: 7606849
Informations de publication
Date de publication:
01 2022
01 2022
Historique:
accepted:
20
06
2021
pubmed:
23
7
2021
medline:
28
1
2022
entrez:
22
7
2021
Statut:
ppublish
Résumé
Rabbit antithymocyte globulins (rATGs) are polyclonal antibodies used to prevent acute cellular rejection in kidney transplantation. Their dosing remains largely empirical and the question of an individualized dose is still unresolved. Data from a prospective study in 17 kidney transplant patients were used to develop a model describing the dose-concentration-response relationship of rATG with T-lymphocyte subpopulation counts over time. The model was validated using an independent cohort of kidney transplant patients treated by rATG in the same center. Pharmacokinetics of rATG was described using a two-compartment model integrating a third compartment and a target-mediated elimination for active rATG. The kinetics of CD3 Our results can be used to design prospective clinical trials testing dose individualization based on patients' characteristics. Eudract No. 2009-012673-35.
Sections du résumé
BACKGROUND
Rabbit antithymocyte globulins (rATGs) are polyclonal antibodies used to prevent acute cellular rejection in kidney transplantation. Their dosing remains largely empirical and the question of an individualized dose is still unresolved.
METHODS
Data from a prospective study in 17 kidney transplant patients were used to develop a model describing the dose-concentration-response relationship of rATG with T-lymphocyte subpopulation counts over time. The model was validated using an independent cohort of kidney transplant patients treated by rATG in the same center.
RESULTS
Pharmacokinetics of rATG was described using a two-compartment model integrating a third compartment and a target-mediated elimination for active rATG. The kinetics of CD3
CONCLUSIONS
Our results can be used to design prospective clinical trials testing dose individualization based on patients' characteristics.
CLINICAL TRIAL REGISTRATION
Eudract No. 2009-012673-35.
Identifiants
pubmed: 34292526
doi: 10.1007/s40262-021-01053-7
pii: 10.1007/s40262-021-01053-7
doi:
Substances chimiques
Antilymphocyte Serum
0
FCGR3A protein, human
0
Immunosuppressive Agents
0
Receptors, IgG
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
111-122Informations de copyright
© 2021. The Author(s), under exclusive licence to Springer Nature Switzerland AG.
Références
Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit antithymocyte globulin (thymoglobulin): 25 years and new frontiers in solid organ transplantation and haematology. Drugs. 2010;70:691–732.
doi: 10.2165/11315940-000000000-00000
Mourad G, Morelon E, Noël C, Glotz D, Lebranchu Y. The role of thymoglobulin induction in kidney transplantation: an update. Clin Transplant. 2012;26:E450–64.
doi: 10.1111/ctr.12021
Cartron G, Dacheux L, Salles G, Solal-Celigny P, Bardos P, Colombat P, et al. Therapeutic activity of humanized anti-CD20 monoclonal antibody and polymorphism in IgG Fc receptor FcgammaRIIIa gene. Blood. 2002;99:754–8.
doi: 10.1182/blood.V99.3.754
Dall’Ozzo S, Tartas S, Paintaud G, Cartron G, Colombat P, Bardos P, et al. Rituximab-dependent cytotoxicity by natural killer cells: influence of FCGR3A polymorphism on the concentration-effect relationship. Cancer Res. 2004;64:4664–9.
doi: 10.1158/0008-5472.CAN-03-2862
Koene HR, Kleijer M, Algra J, Roos D. FcγRIIIa-158V/F polymorphism influences the binding of IgG by natural killer cell FcgammaRIIIa, independently of the FcγRIIIa-48L/R/H phenotype. Blood. 1997;90:1109–14.
doi: 10.1182/blood.V90.3.1109
Wong W, Agrawal N, Pascual M, Anderson DC, Hirsch HH, Fujimoto K, et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int. 2006;19:629–35.
doi: 10.1111/j.1432-2277.2006.00270.x
Ducloux D, Bamoulid J, Daguindau E, Rebibou JM, Courivaud C, Saas P. Antithymocytes globulins: time to revisit its use in kidney transplantation? Int Rev Immunol. 2018;37:183–91.
doi: 10.1080/08830185.2018.1455194
Kho MML, Bouvy AP, Cadogan M, Kraaijeveld R, Baan CC, Weimar W. The effect of low and ultra-low dosages thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol. 2012;26:186–90.
doi: 10.1016/j.trim.2012.02.003
Büchler M, Longuet H, Lemoine R, Herr F, Gatault P, Thibault G, et al. Pharmacokinetic and pharmacodynamic studies of two different rabbit antithymocyte globulin dosing regimens: results of a randomized trial. Transpl Immunol. 2013;28:120–6.
doi: 10.1016/j.trim.2013.03.001
Ternant D, Büchler M, Thibault G, Ohresser M, Watier H, Lebranchu Y, et al. Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients. Pharmacogenet Genomics. 2014;24:26–34.
doi: 10.1097/FPC.0000000000000017
Waller EK, Langston AA, Lonial S, Cherry J, Somani J, Allen AJ, et al. Pharmacokinetics and pharmacodynamics of anti-thymocyte globulin in recipients of partially HLA-matched blood hematopoietic progenitor cell transplantation. Biol Blood Marrow Transplant. 2003;9:460–71.
doi: 10.1016/S1083-8791(03)00127-7
Gatault P, Lajoie L, Stojanova J, Halimi J, Caillard S, Moyrand S, et al. The FcγRIIIA-158 VV genotype increased the risk of post-transplant lymphoproliferative disorder in T-cell-depleted kidney transplant recipients: a retrospective study. Transpl Int. 2020;33:936–47.
doi: 10.1111/tri.13624
Mager DE, Jusko WJ. General pharmacokinetic model for drugs exhibiting target-mediated drug disposition. J Pharmacokinet Pharmacodyn. 2001;28:507–32.
doi: 10.1023/A:1014414520282
Friberg LE, Henningsson A, Maas H, Nguyen L, Karlsson MO. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. J Clin Oncol. 2002;20:4713–21.
doi: 10.1200/JCO.2002.02.140
Zandvliet AS, Schellens JHM, Dittrich C, Wanders J, Beijnen JH, Huitema ADR. Population pharmacokinetic and pharmacodynamic analysis to support treatment optimization of combination chemotherapy with indisulam and carboplatin. Br J Clin Pharmacol. 2008;66:485–97.
doi: 10.1111/j.1365-2125.2008.03230.x
Segura C, Bandrés E, Trocóniz IF, García-Foncillas J, Sayar O, Dios-Vieítez C, et al. Hematological response of topotecan in tumor-bearing rats: modeling of the time course of different cellular populations. Pharm Res. 2004;21:567–73.
doi: 10.1023/B:PHAM.0000022402.00699.5c
Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143–51.
doi: 10.1208/s12248-011-9255-z
Büchler M, Thibault G, Al Najjar A, Valentin J-F, Guerraoui A, Nivet H, et al. Monitoring of ATG therapy by flow cytometry and lymphocyte counts in renal transplantation. Transplant Proc. 1996;28:2817–8.
pubmed: 8908076
Ata P, Kara M, Özdemir E, Canbakan M, Gökçe AM, Bayraktar FA, et al. Monitoring of CD3+ T-cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation. Transplant Proc. 2013;45:929–31.
doi: 10.1016/j.transproceed.2013.02.092
Gurkan S, Luan Y, Dhillon N, Allam SR, Montague T, Bromberg JS, et al. Immune reconstitution following rabbit antithymocyte globulin: immune reconstitution. Am J Transplant. 2010;10:2132–41.
doi: 10.1111/j.1600-6143.2010.03210.x
Lavielle M. mlxR: simulation of longitudinal data. 2019. https://CRAN.R-project.org/package=mlxR . Accessed 28 Jun 2021.
Bunn D, Lea CK, Bevan DJ, Higgins RM, Hendry BM. The pharmacokinetics of anti-thymocyte globulin (ATG) following intravenous infusion in man. Clin Nephrol. 1996;45:29–32.
pubmed: 8616954
Guttmann RD, Caudrelier P, Alberici G. Pharmacokinetics, foreign protein immune response, cytokine release, and lymphocyte subsets in patients receiving thymoglobuline and immunosuppression. Transplant Proc. 1997;29:24S-26S.
doi: 10.1016/S0041-1345(97)80006-1
Regan JF, Lyonnais C, Campbell K, Smith LV, Buelow R, US Thymoglobulin Multi-Center Study Group. Total and active thymoglobulin levels: effects of dose and sensitization on serum concentrations. Transpl Immunol. 2001;9:29–36.
doi: 10.1016/S0966-3274(01)00048-X
Call SK, Kasow KA, Barfield R, Madden R, Leung W, Horwitz E, et al. Total and active rabbit antithymocyte globulin (rATG;Thymoglobulin
doi: 10.1016/j.bbmt.2008.11.027
Admiraal R, van Kesteren C, Jon-van der Zijde CM, van Tol MJD, Bartelink IH, Bredius RGM, et al. Population pharmacokinetic modeling of Thymoglobulin
doi: 10.1007/s40262-014-0214-6
Klaasen RA, Egeland EJ, Chan J, Midtvedt K, Svensson M, Bolstad N, et al. A fully automated method for the determination of serum belatacept and its application in a pharmacokinetic investigation in renal transplant recipients. Ther Drug Monit. 2019;41:11–8.
doi: 10.1097/FTD.0000000000000580
Li H, Han TH, Hunder NN, Jang G, Zhao B. Population pharmacokinetics of brentuximab vedotin in patients with CD30-expressing hematologic malignancies. J Clin Pharmacol. 2017;57:1148–58.
doi: 10.1002/jcph.920
Zierhut ML, Gastonguay MR, Martin SW, Vicini P, Bekker PJ, Holloway D, et al. Population PK–PD model for Fc-osteoprotegerin in healthy postmenopausal women. J Pharmacokinet Pharmacodyn. 2008;35:379–99.
doi: 10.1007/s10928-008-9093-5
Diao L, Li S, Ludden T, Gobburu J, Nestorov I, Jiang H. Population pharmacokinetic modelling of recombinant factor IX Fc fusion protein (rFIXFc) in patients with haemophilia B. Clin Pharmacokinet. 2014;53:467–77.
doi: 10.1007/s40262-013-0129-7
Bouazza N, Urien S, Neven B, Moshous D, Nisoy J, Gabrion A, et al. Evaluation of antithymocyte globulin pharmacokinetics and pharmacodynamics in children. J Allergy Clin Immunol. 2016;137:306-9.e4.
doi: 10.1016/j.jaci.2015.06.003
Djamali A, Turc-Baron C, Portales P, Leverson G, Chong G, Clot J, et al. Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring. Transplantation. 2000;69:799–805.
doi: 10.1097/00007890-200003150-00021
Mohty M, Bacigalupo A, Saliba F, Zuckermann A, Morelon E, Lebranchu Y. New directions for rabbit antithymocyte globulin (Thymoglobulin
doi: 10.1007/s40265-014-0277-6
Nafar M, Dalili N, Poor-Reza-Gholi F, Ahmadpoor P, Samadian F, Samavat S. The appropriate dose of thymoglobulin induction therapy in kidney transplantation. Clin Transplant. 2017;31:e12977.
doi: 10.1111/ctr.12977
Pankewycz O, Leca N, Kohli R, Wallace PK, Said M, Feng L, et al. Low-dose rabbit antithymocyte globulin induction therapy results in prolonged selective lymphocyte depletion irrespective of maintenance immunosuppression. Transplant Proc. 2011;43:462–5.
doi: 10.1016/j.transproceed.2011.01.034